Want to see SE:SOBI full AI Analyst Report?
Top Page
Swedish Orphan Biovitrum AB
(SOBI)
Select Model
Select Model
Rating:58Neutral
Price Target:
kr454.00
▼(-2.95% Downside)
Action:Reiterated
Date:10/17/26
The score is primarily supported by strong cash generation and a generally healthy balance sheet, but is held back by the sharp decline in net profitability (raising earnings volatility risk) and an expensive valuation (very high P/E). Technical signals are neutral-to-mixed and do not materially improve the outlook.
Positive Factors
Revenue Growth
Steady revenue expansion indicates continued demand for Sobi’s rare-disease portfolio and supports a durable commercial foundation. Growth on top of prior annual gains can broaden the earnings base, strengthen reinvestment capacity, and provide operating leverage as the business scales.
Negative Factors
Profitability Decline
The sharp deterioration in net profitability weakens the predictability of Sobi’s earnings despite continued revenue growth and robust EBITDA margins. Thin net margins and much lower net income reduce retained funding capacity and increase the risk that reported results remain volatile over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Steady revenue expansion indicates continued demand for Sobi’s rare-disease portfolio and supports a durable commercial foundation. Growth on top of prior annual gains can broaden the earnings base, strengthen reinvestment capacity, and provide operating leverage as the business scales.
Read all positive factors
Swedish Orphan Biovitrum AB (SOBI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr165.02B
Dividend YieldN/A
Average Volume (3M)292.33K
Price to Earnings (P/E)120.5
Beta (1Y)0.90
Revenue Growth14.79%
EPS Growth26766.85%
CountrySE
Employees1,888
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)3.97
Shares Outstanding357,636,500
10 Day Avg. Volume348,889
30 Day Avg. Volume292,326
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr566.67Price Target Upside21.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)19.22
Revenue Forecast (FY)kr33.29B
Swedish Orphan Biovitrum AB Business Overview & Revenue Model
Company Description
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Ha...
How the Company Makes Money
Sobi makes money primarily by selling prescription rare-disease medicines and recognizing revenue from commercializing products it owns and/or has rights to in specific geographies. The main revenue stream is net product sales generated when Sobi ...
Swedish Orphan Biovitrum AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
66
Positive
Cash Flow
73
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.62B | 28.24B | 26.03B | 22.12B | 18.79B | 15.53B |
| Gross Profit | 14.05B | 12.32B | 20.24B | 9.95B | 13.98B | 12.04B |
| EBITDA | 13.23B | 10.96B | 9.30B | 7.23B | 6.05B | 5.72B |
| Net Income | 1.38B | 478.00M | 3.88B | 2.41B | 2.64B | 2.68B |
Balance Sheet | ||||||
| Total Assets | 82.89B | 67.43B | 75.44B | 74.03B | 52.50B | 48.66B |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 1.04B | 1.14B | 904.00M | 1.36B | 1.04B |
| Total Debt | 17.59B | 11.49B | 16.73B | 20.48B | 9.10B | 10.91B |
| Total Liabilities | 40.62B | 29.71B | 35.15B | 40.16B | 25.97B | 25.46B |
| Stockholders Equity | 42.26B | 37.72B | 40.29B | 33.87B | 26.52B | 23.20B |
Cash Flow | ||||||
| Free Cash Flow | 7.25B | 8.52B | 4.38B | -473.00M | 3.10B | 5.10B |
| Operating Cash Flow | 7.86B | 8.56B | 7.39B | 4.47B | 4.58B | 5.47B |
| Investing Cash Flow | -12.90B | -4.29B | -3.09B | -21.90B | -1.48B | -367.00M |
| Financing Cash Flow | 5.04B | -4.32B | -4.00B | 17.01B | -2.90B | -4.47B |
Swedish Orphan Biovitrum AB Technical Analysis
Positive
467.80
Price Trends
445.96
Positive
451.59
Positive
424.63
Positive
Market Momentum
4.40
Negative
63.50
Neutral
84.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Positive. The current price of 467.8 is above the 20-day moving average (MA) of 439.37, above the 50-day MA of 445.96, and above the 200-day MA of 424.63, indicating a bullish trend. The MACD of 4.40 indicates Negative momentum. The RSI at 63.50 is Neutral, neither overbought nor oversold. The STOCH value of 84.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SOBI.
Swedish Orphan Biovitrum AB Peers Comparison
UnderperformOutperform
Sector (55)
SE:SOBI
Swedish Orphan Biovitrum AB
478.20
150.40
45.88%
SE:HNSA
Hansa Biopharma AB
38.70
4.24
12.30%
SE:MVIR
Medivir AB
1.61
1.07
197.78%
SE:ORX
Orexo AB
4.72
-23.79
-83.46%
SE:NEWBRY
Newbury Pharmaceuticals AB
1.56
-0.55
-26.07%
SE:DICOT
Dicot Pharma AB
0.22
-0.28
-55.82%
Swedish Orphan Biovitrum AB Corporate Events
Sobi Adjusts Share Capital to Support Employee Incentive Programme
Sep 30, 2026
Swedish Orphan Biovitrum has updated its share capital, reporting a total of 357,636,514 common shares and an equal number of votes as of 30 September 2026. The change stems from the issuance and subsequent conversion of 223,677 class C shares int...
Sobi Completes Class C Share Issue to Fund Employee Incentive Programme
Aug 31, 2026
Sobi has completed a directed issue of 223,677 class C shares, subscribed in full by Svenska Handelsbanken AB, raising SEK 122,732.80 to support its long‑term All Employee Programme. The transaction follows authorisation at the May 2026 AGM,...
Sobi partners with Innate Pharma in $580m lacutamab deal to expand rare cancer portfolio
Aug 10, 2026
Sobi has struck a strategic partnership with Innate Pharma to license lacutamab, a first-in-class anti-KIR3DL2 antibody, for cutaneous T-cell lymphoma, securing exclusive global commercial rights upon potential accelerated approval. The deal under...
Sobi CEO Guido Oelkers to Step Down in Early 2027
Aug 3, 2026
Swedish Orphan Biovitrum AB has announced that Chief Executive Officer Guido Oelkers will step down in early 2027 to take a role outside the company, ending nearly a decade of leadership in which Sobi expanded its rare disease portfolio and global...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.